Clik here to view.
Boehringer Ingelheim and Gilead Sign Agreement for HIV Compound Rights
German corporation, Boehringer Ingelheim, and the Californian firm, Gilead Sciences, have entered into a licensing agreement, under which Boehringer Ingelheim has given Gilead exclusive worldwide...
View ArticleClik here to view.
Pradaxa Receives Final Draft OK From NICE
Final draft guidance released from the UK’s National Institute for Health and Clinical Excellence (NICE) recommends the use of Boehringer Ingelheim’s Pradaxa (dabigatran) for the prevention of stroke...
View ArticleClik here to view.
Jentadueto Receives European Commission Marketing Authorisation
European regulators have given approval to Boehringer Ingelheim and Eli Lilly’s diabetes combo drug, Jentadueto. The pharmaceutical organisations announced earlier today that they received marketing...
View ArticleClik here to view.
Boehringer Submits Afatinib to EMA
Boehringer Ingelheim announced earlier today that they have submitted their first oncology compound, afatinib, to European regulators. The German firm filed a marketing authorisation application to the...
View ArticleClik here to view.
Diabetes Drug, Jentadueto, Reaches UK Market
Patients in the UK with type II diabetes now have access to a new alternative for managing their blood glucose levels with the launch of Boehringer Ingelheim/Eli Lilly’s new combination drug,...
View ArticleClik here to view.
Clinical Professionals act as functional provider for Boehringer Ingelheim –...
We are acting as a functional provider for Boehringer Ingelheim – and therefore we are the only recruitment company offering the Clinical Trial Administrator (CTA) roles. Boehringer Ingelheim is one...
View ArticleClik here to view.
Spiolto Respimat Provides Meaningful Quality of Life Improvements in COPD
New data from the Phase IIIb OTEMTO 1&2 trials show Spiolto Respimat provides consistent and clinically meaningful improvements in quality of life versus placebo in patients with chronic...
View ArticleClik here to view.
Lilly/Boehringer diabetes drug Jardiance cuts CV deaths 38%
Eli Lilly and Boehringer Ingelheim’s Jardiance has become the first diabetes drug to show a significant reduction in cardiovascular deaths in a dedicated outcomes study. According to data* from the...
View Article
